Repligen (RGEN) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic vision and market positioning

• Focuses on innovation and aims to be the global leader in bioprocessing, offering a broad, differentiated, data-driven portfolio across filtration, chromatography, analytics, proteins, and ligands.

• Significant expansion in total addressable market from $3 billion to $13 billion over six years, with current sales representing only 2% market share, and operates in a $20B+ bioprocessing market.

• Diversified customer base: no single customer represents more than 7% of revenue, with top 10 customers now accounting for one-third of business, down from two-thirds by top three a decade ago.

• Shift from heavy reliance on monoclonal antibodies to increased exposure in new modalities, now 16% of sales.

• Maintains dual manufacturing in the US and Europe, with a growing focus on Asia and global reach.

Product innovation and portfolio expansion

• Offers one of the broadest portfolios in the industry, spanning fluid management, filtration, chromatography, analytics, proteins, and ligands, with over 80% differentiated and limited competition for key products.

• Launched over 50 new products in five years, with recent launches accounting for 10–12% of 2023–2025 revenue.

• Digitization and PAT technologies are central, with investments in digital twins, advanced analytics, and AI to enhance process efficiency and customer value.

• M&A remains a top priority, with recent acquisitions (e.g., Metenova, 908 Devices) and minority investments (e.g., Novasign) strengthening the portfolio.

• Rapid commercialization enabled by a nimble culture and ongoing product introductions.

Growth strategies and market execution

• Pursues above-market growth through commercial execution, cross-selling, and key account strategies, especially in APAC.

• Commercial excellence and cross-selling have increased products sold per key account by 2.5x since 2019.

• Asia strategy includes new leadership and office openings in Singapore, Japan, and China to accelerate regional growth.

• Product portfolio is well-suited for emerging modalities like ADCs, mRNA, and cell and gene therapy.

• Anticipates a ~2% headwind in FY26 from gene therapy platform shifts.